Studies acute myeloid leukemia with NPM1 mutation and early blood vessel problems
Observes adults with NPM1-mutated acute myeloid leukemia for early blood vessel events.
Plain-language title generated from the registry record
Registry title: Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
Key facts
- Where
- Florence, ItalySee the site
Where in Italy
- SOD Ematologia, Università di Firenze, AOU CareggiFlorence, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Trial code
- NCT07080970
- Record updated
- 22 June 2026
- Original description
This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events.Read full original descriptionShow less
Observational Study on APL-like Subset Within NPM1-mutated Acute Myeloid Leukemia: a Distinct Phenotypic Signature Correlating With Early-onset Vascular Complications. ACTIVATE (APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions)
This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events.
Inclusion: Patients with de novo AML, untreated, newly diagnosed, according to WHO/ICC 2022 criteria from January 2015 onwards; Presence of NPM1 mutation; Availability of immunophenotypic characterization at diagnosis; Age >= 18 years; Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable).
Exclusion: No specific exclusion criteria are provided once eligibility criteria are met.